Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Current therapeutic concepts in mucosa-associated lymphoid tissue (MALT) lymphoma

Current therapeutic concepts in mucosa-associated lymphoid tissue (MALT) lymphoma While eradication of Helicobacter pylori leads to durable remissions in up to 75 % of patients with gastric mucosa-associated lymphoid tissue (MALT) lymphoma and therefore, has been well established as first-line therapy of choice, there is no standard of care for relapsed, refractory or extragastric MALT lymphoma. Both in gastric as well as extragastric MALT lymphoma, local therapy results in high rates of local control, but MALT lymphoma may be disseminated in a significant number of patients, making systemic treatment approaches reasonable. Different classical cytostatic agents have successfully been tested in the past. However, MALT lymphoma usually runs an indolent clinical course and thus, recent trials have focussed on chemotherapeutics with a favourable toxicity profile, e.g. chlorambucil or bendamustine with or without rituximab (R), and new immunomodulatory drugs, e.g. lenalidomide. Results are promising and further, and especially more mature data with a longer follow-up are awaited. In addition, efforts have been made to characterise the activity of antibiotic therapy in extragastric MALT lymphoma, particularly in the setting of ocular adnexal manifestations. Doxycyclin-treatment achieved response rates of 45–65 % in several series, which was independent of the presence of a Chlamydophila psittaci infection. Furthermore, the macrolide antibiotic clarithromycin has become a matter of interest for the treatment of ocular adnexal MALT lymphoma as this substance exerts not only antibiotic, but also direct anti-tumor and immunomodulatory effects. In view of recent data, this short review focuses on highlights and recent results of systemic and antimicrobial therapy in MALT lymphoma. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Current therapeutic concepts in mucosa-associated lymphoid tissue (MALT) lymphoma

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/current-therapeutic-concepts-in-mucosa-associated-lymphoid-tissue-malt-fpyeqYhYdf
Publisher
Springer Journals
Copyright
Copyright © 2014 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-014-0131-2
Publisher site
See Article on Publisher Site

Abstract

While eradication of Helicobacter pylori leads to durable remissions in up to 75 % of patients with gastric mucosa-associated lymphoid tissue (MALT) lymphoma and therefore, has been well established as first-line therapy of choice, there is no standard of care for relapsed, refractory or extragastric MALT lymphoma. Both in gastric as well as extragastric MALT lymphoma, local therapy results in high rates of local control, but MALT lymphoma may be disseminated in a significant number of patients, making systemic treatment approaches reasonable. Different classical cytostatic agents have successfully been tested in the past. However, MALT lymphoma usually runs an indolent clinical course and thus, recent trials have focussed on chemotherapeutics with a favourable toxicity profile, e.g. chlorambucil or bendamustine with or without rituximab (R), and new immunomodulatory drugs, e.g. lenalidomide. Results are promising and further, and especially more mature data with a longer follow-up are awaited. In addition, efforts have been made to characterise the activity of antibiotic therapy in extragastric MALT lymphoma, particularly in the setting of ocular adnexal manifestations. Doxycyclin-treatment achieved response rates of 45–65 % in several series, which was independent of the presence of a Chlamydophila psittaci infection. Furthermore, the macrolide antibiotic clarithromycin has become a matter of interest for the treatment of ocular adnexal MALT lymphoma as this substance exerts not only antibiotic, but also direct anti-tumor and immunomodulatory effects. In view of recent data, this short review focuses on highlights and recent results of systemic and antimicrobial therapy in MALT lymphoma.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Feb 25, 2014

References

  • Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma
    Isaacson, P; Wright, DH
  • Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation
    Suarez, F; Lortholary, O; Hermine, O
  • Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
    Zucca, E; Copie-Bergmann, C; Ricardi, U
  • EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT
    Ruskoné-Fourmestraux, A; Fischbach, W; Aleman, BM
  • Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome
    Tsang, RW; Gospodarowicz, MK; Pintilie, M
  • Primary radiation therapy in patients with localized orbital marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT Lymphoma)
    Son, SH; Choi, BO; Kim, GW
  • Management and long-term results of surgery for localized gastric lymphomas
    Vaillant, JC; Ruskoné-Fourmestraux, A; Aegerter, P
  • Mucosa-associated lymphoid tissue is a disseminated disease in one third of 158 patients analyzed
    Thieblemont, C; Berger, F; Dumontet, C
  • High relapse rate in patients with MALT lymphoma warrants lifelong follow-up
    Raderer, M; Streubel, B; Woehrer, S
  • Mucosa associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled trial
    Avilés, A; Nambo, MJ; Neri, N
  • Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma
    Raderer, M; Wohrer, S; Streubel, B
  • Combination therapy with rituximab and intravenous or oral fludarabine in the first line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue
    Salar, A; Domingo-Domenech, E; Estany, C
  • Treatment of extranodal marginal-zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study
    Jäger, G; Neumeister, P; Brezinschek, R
  • Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression
    Hammel, P; Haioun, C; Chaumette, MT
  • Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis if the IELSG-19 Randomized Study
    Zucca, E; Conconi, A; Laszlo, D
  • Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study
    Lévy, M; Copie-Berman, C; Amiot, A
  • Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie
    Troch, M; Kiesewetter, B; Willenbacher, W
  • A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)
    Kiesewetter, B; Troch, M; Dolak, W
  • Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature
    Kiesewetter, B; Raderer, M
  • Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas
    Ferreri, AJ; Guidoboni, M; Ponzoni, M
  • Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions
    Chanudet, E; Zhou, Y; Bacon, CM
  • Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial
    Ferreri, AJ; Govi, S; Pasini, E
  • First-line therapy with doxycycline in ocular adnexal mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of clinical predictors
    Kim, TM; Kim, KH; Lee, MJ
  • Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial
    Ferreri, AJ; Ponzoni, M; Guidoboni, M
  • Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial
    Govi, S; Dognini, GP; Licata, G
  • Roxithromycin inhibits angiogenesis of human hepatoma cells in vivo by supression VEGF production
    Aoki, D; Ueno, S; Kubo, F